NASDAQ · QTTB
Q32 Bio Inc.
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
Loading market information…
NASDAQ · INTS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Intensity Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.94. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Intensity Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct malignancies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:55 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2024 |
|---|
| Mar 13, 2025 |
| -$5.50+1.79% vs estimate |
| $0.00 |
| Q3 2024 | Nov 13, 2024 | -$6.25+7.41% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $11.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$8.87-$0.19 (-2.1%)
Q32 Bio Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.37% below the high.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$15.41-$0.58 (-3.63%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.31% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$0.81+$0.01 (+1.17%)
iBio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
$6.53+$0.19 (+2.92%)
NextCure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.55% below the high.
$1.20-$0.03 (-2.44%)
Pluri Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.36% below the high.
$3.87-$0.13 (-3.25%)
Plus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.48% below the high.
